Introduction
Hepatocyte growth factor (HGF) plays important roles in cell proliferation, survival, motility, migration, and angiogenesis [2] . Recent studies have shown that abnormal signaling through the only known receptor of HGF, c-Met, with its tyrosine kinase activity, is associated with many types of cancers, and elevated levels of circulating HGF were shown to be correlated with tumor metastasis and cancer progression [21, 24] . These previous findings have led to the development of specific inhibitors of the HGF-cMet pathway as novel therapeutics for various cancers [6, 10, 20] . Small-molecule c-Met tyrosine kinase inhibitors or antibodies directed against c-Met or HGF showed promising therapeutic efficacy in preclinical and clinical trials [7, 13, 16, 18] . Thus, inhibition of HGF/c-Met pathways has emerged as a new paradigm of therapy for the treatment of various types of cancers.
The production of large amounts of antibody is a large burden, particularly when evaluating the in vivo therapeutic potency of multiple antibody leads, because most therapeutic antibodies require high-dose administration, ranging from 5 to 10 mg/kg, over a long period in preclinical and clinical studies. In addition, it is of great importance in the Anti-hepatocyte growth factor (anti-HGF) monoclonal antibodies (mAbs) are potential therapeutics against various cancers. Screening for high-producer clones is a time-consuming and complex process and is a major hurdle in the development of therapeutic mAbs. Here, we describe an efficient approach that allows the selection of high-producer Chinese hamster ovary (CHO) cell lines producing the novel anti-HGF mAb SFN68, which was generated previously by immunizing HGF bound to its receptor c-Met. We selected an SFN68-producing parental cell line via transfection of the dihydrofolate reductase-deficient CHO cell line DG44, which was preadapted to serum-free suspension culture, with an SFN68-expression vector. Subsequent gene amplification via multiple passages of the parental cell line in a methotrexate-containing medium over 4 weeks, followed by clonal isolation, enabled us to isolate two cell lines, 2F7 and 2H4, with 3-fold higher specific productivity. We also screened 72 different media formulated with diverse feed and basal media to develop a suboptimized medium. In the established suboptimized medium, the highest anti-HGF mAb yields of the 2F7 and 2H4 clones were 842 and 861 mg/l, respectively, which were about 10.5-fold higher than that of the parental cell line in a non-optimized basal medium. The selected CHO cell lines secreting high titers of SFN68 would be useful for the production of sufficient amounts of antibodies for efficacy evaluation in preclinical and early clinical studies.
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pharmaceutical industry to shorten the lengthy screening processes for isolating cell lines producing high titers of antibodies with acceptable product quality profiles. For the production of large amounts of antibody in a limited timeline, it is certainly critical to establish a simple approach for cell line establishment and media optimization. For high-level expression of monoclonal antibodies, CHO cells have proven to be most effective [4] . The establishment of highproduction CHO cell lines is initiated by the transfection of an expression vector harboring the target gene and the gene encoding dihydrofolate reductase (DHFR) into DHFRdeficient cells for gene amplification using methotrexate (MTX). However, gene amplification via stepwise increases of the MTX concentration is a time-consuming procedure, and in many cases, it is often difficult to obtain suitable clones because increased specific productivity is prone to be accompanied by metabolic or growth defects [4] . In addition, because the media optimized for one clone may not be effective for other clones when the selected clones are not isogenic (i.e., not derived from the same parental producer cell line), further media optimization, which takes several months using conventional trial-and-error methods, is unavoidable [8] . Furthermore, even when highproducing clones are isolated, their productivity and growth profiles may not be satisfactory in serum-free media. Therefore, selected clones usually need to be adapted to serum-free suspension culture for large-scale production of therapeutic antibodies.
Because antibodies recognizing different epitopes show distinct clinical activities, much effort has been exerted to generate diverse antibodies and screen for higher potency therapeutic antibodies against HGF. Currently, several monoclonal antibodies against HGF have been developed, and their tumor suppressive potency was demonstrated in xenograft mouse models [3, 5, 12, 14] . The recombinant monoclonal antibody SFN68, which we sought to produce in the present work, is unique among HGF-neutralizing antibodies in that it was generated by immunizing the HGF-c-Met complex [11] . The potential advantage of SFN68 over other anti-HGF antibodies elicited by immunizing HGF only appears to be its higher specificity for the HGF-cMet interaction. The epitope of SFN68 was characterized to be nonlinear, and this novel chimeric monoclonal antibody was shown to block the HGF-c-Met interaction and prevent cell scattering and proliferation [11] .
To evaluate the toxicity and anticancer efficacy of SFN68, high-producer cell line establishment is required to provide a substantial amount of antibodies for preclinical and clinical studies. In the present work, we established CHO cell lines producing high levels of the anti-HGF antibody SFN68 using serum-free suspension cultureadapted CHO cells. We report a simple approach for the rapid, effective selection of high anti-HGF antibodyproducing clones. Furthermore, we analyzed the growth and antibody production profiles of the selected highproducer CHO cell clones in batch cultures with suboptimized medium.
Materials and Methods

Cell Lines and Cell Culture
The CHO cell lines expressing the anti-HGF monoclonal antibody (mAb) SFN68 were established by transfection of the serum-free suspension culture-adapted DHFR-deficient CHO cell line DG44 (Invitrogen, USA) with an expression vector harboring the cDNA for the anti-HGF mAb SFN68 under the control of the CMV promoter, the DHFR-coding gene required for gene amplification using MTX, and a neomycin resistance gene as a selection marker. The cDNA for SFN68 was designed to produce an intact antibody composed of SFN68 Fab and the human IgG1 Fc fragment [11] . Stable CHO cell lines were selected by growing the transfected cells in the presence of 250 µg/ml G418 for 3-4 weeks. CHO cells were cultured in plates containing CD OptiCHO (Invitrogen) medium supplemented with 8 mM L-glutamine, termed basal medium unless otherwise stated, at 37 o C and 5% CO 2 . For cultivation in 125 ml Erlenmeyer shaker flasks with agitation at 130 rpm, a Multitron (Infors AG, Switzerland) incubator was used to grow cells under the conditions of 8% CO 2 and 55% humidity. To formulate the suboptimized media, commercially available chemically defined media, including CD OptiCHO (Invitrogen), CDM4CHO (Hyclone, USA), CDM4mab (Hyclone), PowerCHO (Lonza, Belgium), ProCHO5 (Lonza), ExCell 302 (SAFC Biosciences, USA), ExCell DHFR (SAFC Biosciences), and ExCell CD (SAFC Biosciences), were used as basal media. Powerfeed (Lonza), CHO CD Efficient Feed B (Invitrogen), CD Feed 3 (SAFC Biosciences), and Cell Boost kit (Hyclone) were used as feed media. Each feed medium was added to the individual basal media to a final concentration of 15% (v/v) on day 0. All media used for CHO cell cultivation were supplemented with 8 mM L-glutamine.
Selection of SFN68 High Producers by Gene Amplification
The parental SFN68-producing CHO cell line was subjected to multiple passages in CD OptiCHO basal medium containing 500 nM MTX (Sigma-Aldrich, USA). At each passage step, cells were collected by centrifugation, washed, and transferred to fresh medium containing 500 nM MTX. When cells were adapted to the MTX-containing basal medium, they were transferred to 96-well culture plates for isogenic clone isolation by the limiting-dilution method. When subclones formed cell colonies in each well, the anti-HGF mAb concentration in the culture supernatant was measured by enzyme-linked immunosorbent assay (ELISA). The
